Literature DB >> 23830211

Involvement of levels of Toll like receptor-4 in monocytes, CD4+ T-lymphocyte subsets, and cytokines in patients with immune thrombocytopenic purpura.

Hongyun Liu1, Xianfeng Ouyang, Yiqing Li, Hua Zeng, Xiuju Wang, Shuangfeng Xie, Danian Nie, Jie Xiao, Jing Wei, Yudan Wu, Songmei Yin, Liping Ma.   

Abstract

INTRODUCTION: Toll-like receptors have been found to be associated with immune-mediated diseases but it is still not clear whether they play a role in immune thrombocytopenic purpura (ITP), especially TLR4. CD4+ T-lymphocyte abnormalities, including Th17, Th1, Th2, and regulator T cell (Treg), are considered important in ITP. There have been few studies regarding the expression of TLR4 and the relationships between TLR4 and Th17 levels in ITP.
MATERIALS AND METHODS: In this study, we evaluated the expression of TLR4 in monocytes, the plasma concentrations of IL-23, IL-17 and the profiles of Th17, Th1, Th2 cells in 70 patients with ITP and 31 healthy controls. In addition, we evaluated IL-2 and Treg cells in 46 cases of 70 patients with ITP and the same 31 controls.
RESULTS: Higher levels of TLR4 expression, higher relative numbers of Th17 and Th1 cells and lower levels of Treg cells were observed in patients when compared with controls (p=0.001 for TLR4; p<0.001 for Th17; p=0.014 for Th1; p=0.001 for Treg). The levels of IL-23 and IL-2 were increased (p=0.022 for IL-23; p=0.025 for IL-2), the relative levels of Th2 and concentrations of IL-17 were similar across both groups (p=0.446 for Th2; p=0.316 for IL-17). A significant negative correlation was observed between levels of TLR4 and Treg(r=-0.544, p<0.001), but a significantly positive correlation was observed between IL-2 and IL-23 concentration in patients (r=0.441, p=0.004). Neither the correlation between TLR4 and the other CD4(+) T cells and cytokines nor the correlation between the three cytokines and CD4+ T cells was found to be statistically significant.
CONCLUSIONS: Our data showed that TLR4, CD4+ T cells (Th1, Th17 and Treg cells) and related cytokines (IL-23, IL-2) may take part in the pathogenesis of ITP. TLR4 may play a role through the TLR4-cytokine-CD4+ T lymphocyte cell pathway.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD4+T lymphocyte subsets; IFN-γ; IL-17; IL-2; IL-23; ITP; T helper 1 cells; T helper17 cells; T helper2 cells; T regulator cells; TLR4; Th1; Th17; Th2; Toll like receptor-4; Treg; immune thrombocytopenia; immune thrombocytopenic purpura; interferon-γ; interleukin-17; interleukin-2; interleukin-23

Mesh:

Substances:

Year:  2013        PMID: 23830211     DOI: 10.1016/j.thromres.2013.04.025

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  11 in total

1.  Circulating level of Th17 cells is associated with sensitivity to glucocorticoids in patients with immune thrombocytopenia.

Authors:  YiChan Zhang; TingTing Ma; Xuan Zhou; JunHao Chen; Juan Li
Journal:  Int J Hematol       Date:  2018-01-11       Impact factor: 2.490

2.  Exploring the Potential of Eltrombopag: Room for More?

Authors:  Francesco Tarantini; Cosimo Cumbo; Luisa Anelli; Antonella Zagaria; Maria Rosa Conserva; Immacolata Redavid; Giorgina Specchia; Pellegrino Musto; Francesco Albano
Journal:  Front Pharmacol       Date:  2022-05-23       Impact factor: 5.988

3.  Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach.

Authors:  Maria L Lozano; Cristina Segú-Vergés; Mireia Coma; María T Álvarez-Roman; José R González-Porras; Laura Gutiérrez; David Valcárcel; Nora Butta
Journal:  Int J Mol Sci       Date:  2021-06-27       Impact factor: 5.923

4.  The role of IL-23/Th17 pathway in patients with primary immune thrombocytopenia.

Authors:  Xin Ye; Lei Zhang; Hui Wang; Yan Chen; Weiwei Zhang; Rongrong Zhu; Chaoping Fang; Anmei Deng; Baohua Qian
Journal:  PLoS One       Date:  2015-01-26       Impact factor: 3.240

5.  Biomarkers for immune thrombocytopenia.

Authors:  Chunmei Zhang; Liping Zhang; Lingjia Yu; Yongyu Shi; Xuebin Ji
Journal:  Biomark Res       Date:  2015-07-16

6.  Plasma Levels of Interleukin 12 Family Cytokines and Their Relevant Cytokines in Adult Patients with Chronic Immune Thrombocytopenia before and after High-Dose Dexamethasome Treatment.

Authors:  Qingsheng Li; Linjie Zhang; Ruixiang Xia; Qingshu Zeng; Yongqing Wang; Liang Xia; Leiming Xia; Mingzhen Yang
Journal:  Med Princ Pract       Date:  2015-06-23       Impact factor: 1.927

7.  Low mucosal-associated invariant T-cell number in peripheral blood of patients with immune thrombocytopenia and their response to prednisolone.

Authors:  Takaaki Maekawa; Yukiko Osawa; Yosuke Okada; Noriaki Tachi; Masahiro Teramoto; Toshikuni Kawamura; Toshikatsu Horiuchi; Shoichiro Kato; Ayako Kobayashi; Shinichi Kobayashi; Ken Sato; Fumihiko Kimura
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

8.  Predicting bleeding risk in a Chinese immune thrombocytopenia (ITP) population: development and assessment of a new predictive nomogram.

Authors:  Mingjing Wang; Weiyi Liu; Yonggang Xu; Hongzhi Wang; Xiaoqing Guo; Xiaoqing Ding; Richeng Quan; Haiyan Chen; Shirong Zhu; Teng Fan; Yujin Li; Xuebin Zhang; Yan Sun; Xiaomei Hu
Journal:  Sci Rep       Date:  2020-09-18       Impact factor: 4.379

9.  HUWE1 Causes an Immune Imbalance in Immune Thrombocytopenic Purpura by Reducing the Number and Function of Treg Cells Through the Ubiquitination Degradation of Ets-1.

Authors:  Jianqin Li; Yalin Xia; Xiaoru Fan; Xiaofang Wu; Feiyun Yang; Shaoyan Hu; Zhaoyue Wang
Journal:  Front Cell Dev Biol       Date:  2021-11-25

Review 10.  Immune Thrombocytopenic Purpura as a Hemorrhagic Versus Thrombotic Disease: An Updated Insight into Pathophysiological Mechanisms.

Authors:  Claudia Cristina Tărniceriu; Loredana Liliana Hurjui; Irina Daniela Florea; Ion Hurjui; Irina Gradinaru; Daniela Maria Tanase; Carmen Delianu; Anca Haisan; Ludmila Lozneanu
Journal:  Medicina (Kaunas)       Date:  2022-02-01       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.